The work of our Screening and Trials initiative has immediate benefits to people with dementia and Alzheimer’s disease by attracting to Australia major clinical trials and providing patients with access to novel therapies.
ADNeT’s development of screening sites around the country and a database of pre-qualified suitable trial participants was central to bringing the Eisai Clarity trial to Australia.
The phase III clinical study will evaluate the efficacy of BAN2401 – an antibody that targets amyloid plaques in the brain, one of the key pathological hallmarks of Alzheimer’s Disease – in participants with early Alzheimer’s disease (EAD) aged between 50 and 90 years. The study will comprise 1,500 patients worldwide.
The Eisai Clarity trial has begun recruiting, with trial sites announced in NSW, QLD, SA, WA, and VIC.
Clinicians who would like their patients to be considered for this and other trials, should in the first instance contact email@example.com.
While a detailed screening by ADNeT does not guarantee trial participation, it will provide the treating doctor key information about the person’s suitability for this and/or other future trials running in Australia.
“ADNeT’s screening program in each state as an avenue for faster recruitment into trials attracted Eisai to Australia and will help speed the development of a very promising disease modifying therapy”, said Prof Chris Rowe. “It will also bring in over $10 million to the Australian economy.”
For more information, contact Dr Jo Robertson, Clinical Neuropsychologist (MPsych, PhD), Screening and Trials Coordinator
T: +61 408 508 121